Factors Influencing Retinal Pigment Epithelium-Atrophy Progression Rate in Stargardt Disease
- PMID: 32832238
- PMCID: PMC7414677
- DOI: 10.1167/tvst.9.7.33
Factors Influencing Retinal Pigment Epithelium-Atrophy Progression Rate in Stargardt Disease
Abstract
Purpose: To evaluate demographic, clinical, imaging, and genetic factors associated with retinal pigment epithelium enlargement in Stargardt disease (STGD1) and to measure the agreement between short-wavelength fundus autofluorescence (SW-FAF) and near-infrared fundus autofluorescence (NIR-FAF).
Methods: Retrospective cohort study of patients with STGD1 with ≥2 gradable SW-FAF images. RPE-atrophy areas were measured on SW-FAF and NIR-FAF at each visit and regressed against time to obtain the rate of RPE-atrophy enlargement. Agreement between SW-FAF and NIR-FAF with regards to baseline atrophic areas and rates of enlargement was evaluated. Baseline factors predictive of faster SW-FAF RPE-atrophy enlargement were investigated with linear mixed models.
Results: Fifty-four eyes of 28 patients (median age: 45 years; 13 males) were included. SW-FAF and NIR-FAF agreed well for slow rates of RPE-atrophy progression, but agreement decreased as the rate increased. Median (interquartile range [IQR]) rate of RPE-atrophy expansion was 0.18 (0.10-0.85) mm2/year on SW-FAF and 0.24 (0.08-0.33) mm2/year on NIR-FAF. Larger baseline RPE-atrophy area (estimate: 0.057 mm2/year, P < 0.001), worse visual acuity (0.305 mm2/year, P = 0.005), multifocal disease (0.401 mm2/year, P = 0.02), and SW-FAF pattern (0.534 mm2/year, P =0 .03) were associated with a faster rate of progression (predictive R2: 0.65).
Conclusions: SW-FAF and NIR-FAF are not interchangeable in the evaluation of RPE-atrophy enlargement, and both imaging modalities may be required for optimal detection of disease progression. A multivariable model based on baseline clinical and imaging information may identify patients at higher risk of fast disease progression.
Translational relevance: The knowledge of the agreement of different FAF modalities, the estimated rates of RPE-atrophy enlargement, and factors predictive of faster anatomic decay in STGD1 may allow tailored clinical management and better clinical trials design.
Keywords: Stargardt disease; best-corrected visual acuity; disease progression; near-infrared autofluorescence; short-wavelength autofluorescence.
Copyright 2020 The Authors.
Conflict of interest statement
Disclosure: M.V. Cicinelli, None; A. Rabiolo, None; M. Brambati, None; C. Viganò, None; F. Bandello, Allergan (C), Bayer (C), Boehringer-Ingelheim (C), Hoffmann La Roche (C), Novartis (C), NTC Pharma (C), Sifi (C), Thrombogenics (C), Zeiss (C), Sooft (R). M. Battaglia Parodi, None
Figures
References
-
- Fujinami K, Lois N, Mukherjee R, et al.. A longitudinal study of Stargardt disease: quantitative assessment of fundus autofluorescence, progression, and genotype correlations. Invest Ophthalmol Vis Sci. 2013; 54: 8181–8190. - PubMed
-
- Han Z, Conley SM, Naash MI. Gene therapy for Stargardt disease associated with ABCA4 gene. Adv Exp Med Biol. 2014; 801: 719–724. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
